Opioids
are generally prescribed for treating pain. The opioid drug class
includes morphine, hydrocodone, oxycodone, heroin, codeine, morphine,
fentanyl, and methadone. It is also used as a cough suppressant and
in diarrhea treatment. Opioids can be administered either through
pills, liquids, intravenous, transdermal patches, or lozenges.
Developed countries in North America and Europe are notorious for the
high levels of abuse of this drug. Drugs such as codeine, morphine,
fentanyl, and hydrocodone have become a source of addiction,
especially among the population in these regions due to easy
availability of the drugs in these regions. According to the World
Drug Report 2016, a staggering 17.4 million people were affected by
opioid drug abuse in 2014. However, global organizations and
regulatory agencies such as the FDA, Centers for Disease Control and
Prevention (CDC) and World Health Organization (WHO) are working
towards limiting the abuse of opioids by creating awareness and
educating prescribers to be cautious while prescribing these drugs.
In 2016, the CDC issued guidelines to prescribe opioids, limiting the
daily dose of opioids to 90 morphine milligram equivalent (MME).
Ask
Sample Copy of Research @
https://www.coherentmarketinsights.com/insight/request-sample/135
Market
Dynamics
According
to the National Institutes of Health (NIH) estimates published in
2015 by the American Pain Society, nearly 50 million people in the
U.S. suffered from chronic pain. Use of opioids in cancer pain,
orthopedic pain, neuropathic pain, post-operative pain, and lower
back pain is very effective. With growing incidence of chronic pain,
demand for opioids will also increase consequently.
The
global opioids market was valued at US$ 17,132.5 million in 2015 and
is expected to witness a moderate CAGR of 4.2% during the forecast
period (2016 – 2024).
Market
Key Players
Key
companies covered as a part of this study include Purdue Pharma L.P.,
Janssen Pharmaceuticals, Inc., West - Ward Pharmaceuticals
Corporation, Pfizer, Inc., Egalet Corporation, Allergan plc, Sanofi
SA, Boehringer Ingelheim, and Sun Pharmaceutical Industries Ltd.
Increasing
prevalence of chronic pain is expected to drive the opioids market
growth
According
to the American Academy of Pain Medicine (2011), the number of people
who suffered from chronic pain was around 1.8 billion. Moreover,
according to the NIH estimates (2015), one in 10 people in the U.S.
suffer from chronic pain. Around one-third to half of the population
in the U.K. suffers from chronic pain, according to a study published
in the British Medical Journal in 2016. Opioids are commonly used for
treating pain, and opioid containing drugs are being misused or are
being consumed in overdose when patients follow self-medication.
Moreover, rising prevalence of pain, cough and, diarrhea are other
factors driving growth of the opioids agonist drugs market. The
highly prescribed opioid in the U.S. is hydrocodone.
Detailed
Segmentation:
Global
Opioids Agonist Drugs Market, By Product Type:
Codeine
Fentanyl
Meperidine
Methadone
Morphine
Hydrocodone
Read
More Details About Opioids
Market
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment